FACTS: Frequency Therapeutics’s most recent trial data on FX-322 demonstrates reversal of hearing loss is very real and might be hitting markets in the near future. The hearing test focuses on improving speech perception those with sensorineural hear loss (SNHL). So far, three of four trials of 200 patients have shown promising results and more hearing tests are coming soon. Tinnitus is also being evaluated as an exploratory measure with FX-322 by using the Tinnitus Functional Index (TFI). Want to learn more and become a participant? See Below.
SOURCE: Frequency is currently enrolling new patients for hearing test click here.